# Effect of Pexelizumab on All-Cause Mortality and Myocardial Infarction in Patients Undergoing Coronary Artery Bypass Graft Surgery With Cardio-Pulmonary Bypass

> **NCT00048308** · PHASE3 · COMPLETED · sponsor: **Alexion Pharmaceuticals, Inc.** · enrollment: 3000 (—)

## Conditions studied

- Cardio-pulmonary Bypass
- Coronary Artery Bypass Graft

## Interventions

- **DRUG:** pexelizumab

## Key facts

- **NCT ID:** NCT00048308
- **Lead sponsor:** Alexion Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-01
- **Primary completion:** 2003-03
- **Final completion:** —
- **Target enrollment:** 3000 (—)
- **Last updated:** 2017-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00048308

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00048308, "Effect of Pexelizumab on All-Cause Mortality and Myocardial Infarction in Patients Undergoing Coronary Artery Bypass Graft Surgery With Cardio-Pulmonary Bypass". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00048308. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*